ISSN 0018-6694
Vol. 45, Issue 5, 2009February 22, 2009 CDT
Reconsidering Patent Licensing in the Aftermath of Medimmune
Reconsidering Patent Licensing in the Aftermath of Medimmune
Articles in Vol. 45, Issue 5, 2009
Vol. 45, Issue 5, 2009
- Dealing with the Realities of Race and Ethnicity: A Bioethics-Centered Argument in Favor of Race-Based Genetics ResearchMichael J. Malinowski
- Defining "Race" as the Defining ProblemTimothy Caulfield
- Rejecting Race as a Critical Marker of Human Biomedical DifferenceCheryl Mwaria
- Respecting, Rather than Reacting to, Race in Basic Biomedical Research: A Response to Professors Caulfield and Mwaria,Michael Malinowski
- Categorical Bars to Execution: Civilizing the Death PenaltyRobert Batey
- Kidneys, Cash, and Kashrut: A Legal, Economic, and Religious Analysis of Selling KidneysRobert Steinbuch
- Reconsidering Patent Licensing in the Aftermath of _Medimmune_Liza Vertinsky
- Preemption by StealthSandra Zellmer
- Abortion from Privacy to Equality: the Failure of the Justifications for Taking Human LifeRobert John Araujo
- Determining Facts: The Myth of Direct EvidenceRichard Greenstein
- Death by Association: Conspiracy Liability and Capital Punishment in TexasOmar Ebeid
- Twice Bitten: Denial of the Right to Counsel in Successive Prosecutions by Separate SovereignsDavid Lane
Liza Vertinsky, Reconsidering Patent Licensing in the Aftermath of Medimmune, 45 Hou. L. Rev. (2009).